UBS Has Nine Biotech Buyout and Merger Candidates – 24/7 Wall St.
Puma Biotech punts near $300 million on Takeda discard
5 Best Biotech Stocks for 2018 | InvestorPlace
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Why Puma Biotech Could Get Acquired Between July to September of This Year | BioSpace
A Licensing Agreement Won't Protect This Biotech From A Takeover | Investor's Business Daily
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Opinion: 15 biotech stocks to put on your watch list now - MarketWatch
Puma Biotechnology
Is Puma Biotechnology a Buy? | The Motley Fool
The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: A Speculative Investment At A Discount (NASDAQ:PBYI) | Seeking Alpha
Goldman Recommends Selling Puma Biotech, Clovis Oncology; Cites Company-Specific, Competitive Risks
Puma pounces on failed Takeda drug, snapping up cancer prospect
Why Puma Biotechnology Is Soaring Today | The Motley Fool
Puma Biotechnology
Puma Biotechnology: Who Are They? What Happened? And, Where Are They Going? (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
With 53% institutional ownership, Puma Biotechnology, Inc. (NASDAQ:PBYI) is a favorite amongst the big guns | Nasdaq
Puma Shares Soar 81% Over 2 Days - Los Angeles Business Journal
Puma Shares Soar 81% Over 2 Days - Los Angeles Business Journal
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib | Nasdaq
